Imidazo[1,2-]pyridazines As IL-17A Inhibitors for Treating Psoriasis, Rheumatoid Arthritis, and Multiple Sclerosis
Overview
Overview
Journal
ACS Med Chem Lett
Publisher
American Chemical Society
Specialty
Chemistry
Date
2021 Oct 22
PMID
34676030
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Stober C
. Pathogenesis of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021; 35(2):101694.
DOI: 10.1016/j.berh.2021.101694.
View
2.
Griffiths C, Armstrong A, Gudjonsson J, Barker J
. Psoriasis. Lancet. 2021; 397(10281):1301-1315.
DOI: 10.1016/S0140-6736(20)32549-6.
View
3.
Ghoreschi K, Balato A, Enerback C, Sabat R
. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021; 397(10275):754-766.
DOI: 10.1016/S0140-6736(21)00184-7.
View
4.
W Marson J, Snyder M, Lebwohl M
. Newer Therapies in Psoriasis. Med Clin North Am. 2021; 105(4):627-641.
DOI: 10.1016/j.mcna.2021.04.004.
View
5.
Loft N, Halling A, Egeberg A, Skov L
. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol. 2020; 84(1):130-138.
DOI: 10.1016/j.jaad.2020.07.085.
View